{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:49:30Z","timestamp":1790790570287,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["310718\/2021-0"],"award-info":[{"award-number":["310718\/2021-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["371\/2021"],"award-info":[{"award-number":["371\/2021"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005668","name":"Funda\u00e7\u00e3o de Apoio \u00e0 Pesquisa do Distrito Federal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030774","name":"Sociedade Brasileira de Reumatologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2019\/09068-3"],"award-info":[{"award-number":["2019\/09068-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.semarthrit.2024.152563","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T22:39:19Z","timestamp":1727822359000},"page":"152563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials"],"prefix":"10.1016","volume":"69","author":[{"given":"Alisson","family":"Pugliesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Gomes Chicre","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vani Abreu de Souza","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia de Oliveira","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline Gon\u00e7alves","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia de Castro Silveira","family":"Bichuette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoraida","family":"Sachetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6465-356X","authenticated-orcid":false,"given":"Luiz S\u00e9rgio F.","family":"de Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoel Barros","family":"Bertolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2024.152563_bib0001","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0002","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol Nature Publishing Group"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0003","first-page":"652","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"New England J Med Massachusetts Med Society"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0004","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0005","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0006","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of Janus Kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0008","unstructured":"Research C for DE and. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. FDA [Internet] FDA; 2021 [cited 2023 Feb 20]; Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death."},{"key":"10.1016\/j.semarthrit.2024.152563_bib0009","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: the theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat Rev Rheumatol Nature Publishing Group"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0010","doi-asserted-by":"crossref","first-page":"e757","DOI":"10.1016\/S2665-9913(21)00323-4","article-title":"FDA expands JAK inhibitors warning: going beyond the data?","volume":"3","author":"Thorley","year":"2021","journal-title":"The Lancet Rheumatology Elsevier"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0011","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheumatic Dis BMJ Publishing Group Ltd"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0012","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial","volume":"72","author":"Giles","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0013","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1136\/annrheumdis-2017-211708","article-title":"Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis","volume":"76","author":"Robertson","year":"2017","journal-title":"Ann Rheumat Dis BMJ Publishing Group Ltd"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0014","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0015","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Medicine Public Library Science"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0016","unstructured":"Diretrizes metodol\u00f3gicas: sistema GRADE \u2013 Manual de gradua\u00e7\u00e3o da qualidade da evid\u00eancia e for\u00e7a de recomenda\u00e7\u00e3o para tomada de decis\u00e3o em sa\u00fade. 2014."},{"key":"10.1016\/j.semarthrit.2024.152563_bib0017","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Green S, Cochrane Collaboration, editors. Cochrane handbook for systematic reviews of interventions. Chichester, England; Hoboken, NJ: Wiley-Blackwell; 2008. 649 p.","DOI":"10.1002\/9780470712184"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0018","series-title":"Chapter 11: undertaking network meta-analyses [Internet]","year":"2024"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0019","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence Synthesis for Decision Making 2: a Generalized Linear Modeling Framework for Pairwise and Network Meta-analysis of Randomized Controlled Trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making SAGE Publications Inc STM"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0020","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0021","first-page":"67","article-title":"Likelihood of reaching minimal clinically important difference in adult spinal deformity: a comparison of operative and nonoperative treatment","volume":"14","author":"Liu","year":"2014","journal-title":"Ochsner J"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0022","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jacc.2009.06.065","article-title":"Trial and error. How to avoid commonly encountered limitations of published clinical trials","volume":"55","author":"Kaul","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0023","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.jval.2022.07.010","article-title":"Is IQWiG's 15% Threshold Universally Applicable in Assessing the Clinical Relevance of Patient-Reported Outcomes Changes? An ISPOR Special Interest Group Report","volume":"25","author":"Schlichting","year":"2022","journal-title":"Value in Health Elsevier"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0024","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/j.jacc.2004.01.035","article-title":"Prior convictions: bayesian approaches to the analysis and interpretation of clinical megatrials","volume":"43","author":"Diamond","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0025","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/annrheumdis-2015-207628","article-title":"Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial","volume":"75","author":"Burmester","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0007","first-page":"316","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"New England J Med Massachusetts Medical Soc"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0026","first-page":"2377","article-title":"Tofacitinib versus Methotrexate in Rheumatoid Arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"New England J Med Massachusetts Medical Society"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0027","first-page":"508","article-title":"Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"New England J Med Massachusetts Medical Society"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0028","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"The Lancet Elsevier"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0029","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheumatic Dis BMJ Publishing Group Ltd"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0030","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0031","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"The Lancet Elsevier"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0032","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"The Lancet Elsevier"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0033","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0034","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"The Lancet Elsevier"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0035","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/acr.22384","article-title":"Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis","volume":"66","author":"Kivitz","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0036","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/ard.2010.148700","article-title":"Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study","volume":"71","author":"Yazici","year":"2012","journal-title":"Ann Rheumatic Dis BMJ Publishing Group Ltd"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0037","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3899\/jrheum.120447","article-title":"Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE Study 2-year Results","volume":"40","author":"Fleischmann","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0038","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheumatism"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0039","series-title":"EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders [Internet]","year":"2022"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0040","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s42358-021-00228-x","article-title":"Recommendations of the Brazilian Society of Rheumatology for the use of JAK inhibitors in the management of rheumatoid arthritis","volume":"61","author":"Bonfiglioli","year":"2021","journal-title":"Advances in Rheumatology"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0041","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheumatic Dis BMJ Publishing Group Ltd"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0042","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/mr\/roac017","article-title":"Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication","volume":"33","author":"Kawahito","year":"2023","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0043","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3899\/jrheum.220209","article-title":"Canadian rheumatology association living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying antirheumatic drugs","volume":"49","author":"Hazlewood","year":"2022","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0044","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/annrheumdis-2022-eular.2686","article-title":"OP0268 comparison of major cardiovascular and thromboembolic events in safety reports between rheumatoid arthritis patients treated with jak inhibitors versus anti-TNF: results from VigiBase","volume":"81","author":"Montastruc","year":"2022","journal-title":"Ann Rheumatic Dis BMJ Publishing Group Ltd"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0045","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/ard-2022-222824","article-title":"Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study","volume":"82","author":"Hoisnard","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0046","unstructured":"Eli Lilly and Company.A Randomized, Active-Controlled, Parallel-Group, Phase 3b\/4 Study of Baricitinib in Patients With Rheumatoid Arthritis [Internet]. clinicaltrials.gov; 2024 Apr. Report No.: NCT03915964. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03915964."},{"key":"10.1016\/j.semarthrit.2024.152563_bib0047","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis","volume":"379","author":"Swerdlow","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0048","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/art.39098","article-title":"Disease activity in rheumatoid arthritis and the risk of cardiovascular events","volume":"67","author":"Solomon","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152563_bib0049","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/s41440-020-0441-1","article-title":"Traditional cardiovascular risk factors and residual disease activity are associated with atherosclerosis progression in rheumatoid arthritis patients","volume":"43","author":"Dalbeni","year":"2020","journal-title":"Hypertens Res Nature Publishing Group"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224002038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224002038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:19:31Z","timestamp":1778663971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017224002038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":49,"alternative-id":["S0049017224002038"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152563","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152563"}}